Men's Health

A new study assesses how a biopsy-based gene test impacts prostate cancer treatment recommendations in three high-volume practices.

Products in the pipeline for prostate cancer, bladder cancer, and much more.

Post-radical prostatectomy radiation therapy in patients at risk of prostate cancer recurrence is on the wane in the U.S., despite evidence and guidelines supporting the practice, recently published research indicates.

A patient follow-up report shows promising mid-term results from five German urology centers that implemented the prostatic urethral lift (UroLift System, NeoTract, Inc.) to alleviate symptomatic BPH in patients suffering from mild, moderate, and even severe obstruction.

Biomarker models to predict disease progression in prostate cancer have a promising future, but at present, they have not fully justified their claimed clinical utilities, according to the authors of an independent review and analysis of the literature.

Laser photoselective vaporization prostatectomy using a 180W 532-nm lithium triborate laser (GreenLight XPS-180W laser system, American Medical Systems) is a safe and efficient option for treating BPH in men at high risk for surgical complications, according to findings from a large, international retrospective analysis.

Other products featured include a spacer system to protect men undergoing PCa radiotherapy, a pelvic floor exercise app, and more.

I am more optimistic that we will find a way to treat those who truly need to be treated and follow those unlikely to die from their disease.

In this article, James M. Hotaling, MD, MS, outlines the elements that comprise a cost-effective workup of the infertile male patient.

A newly published review suggests that age-related testosterone deficiency treatment with intramuscular injections of testosterone replacement therapy offers health benefits and lower cardiovascular risk compared to testosterone replacement by patch or gel.

Placement of a nerve “wrap” around the neurovascular bundle during nerve-sparing robot-assisted radical prostatectomy appears to accelerate the early restoration of continence and potency following surgery, a recently published study has shown.

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

To help you maximize your AUA experience, Urology Times’ editorial board and other thought leaders have pored over hundreds of abstracts to identify the key trends and can’t-miss research from this year’s meeting.

Statins may improve outcomes in hormone-sensitive prostate cancer, and one possible mechanism responsible may have been discovered.

The findings could help clinicians differentiate between slow-growing and aggressive tumors

The FDA has granted clearance to a hydrogel spacer for prostate cancer patients undergoing radiotherapy.

Final analysis of a phase III trial shows abiraterone acetate (ZYTIGA) plus prednisone extended overall survival compared to placebo plus prednisone in chemotherapy-naive men with mCRPC.

Recent phase II results point to the efficacy of the prostate cancer agent enzalutamide (XTANDI) when compared with bicalutamide (Casodex).

Men with prostate cancer who meet the criteria for active surveillance and undergo delayed radical prostatectomy after a period of active surveillance do not have a higher risk of adverse pathology compared with men with similar pre-treatment biopsy features who undergo immediate prostatectomy.

In men who take the 5-alpha-reductase inhibitor finasteride (Propecia) for hair loss, published data on its sexual side effects are insufficient to create a safety profile of the drug, according to a recent study.

Charles J. Ryan, MD, recently presented the final analysis of the COU-AA-302 study of abiraterone acetate (ZYTIGA) versus placebo.

Christopher Amling, MD, describes strategies to reduce skeletal-related morbidity, including lifestyle changes, calcium and vitamin D supplementation, and pharmacologic therapy.

An iodine-125 low-dose-rate brachytherapy boost outperformed dose-escalated external beam radiotherapy boost in achieving biochemical progression-free survival in men with unfavorable risk prostate cancer, according to results of a recent multicenter trial.

The major organizations representing urologists are continuing their push for congressional approval of legislation designed to reform the operations of the U.S. Preventive Services Task Force, which in May 2012 recommended against PSA-based screening for prostate cancer.

Results presented at the EAU Annual Congress bolster the Prolaris test’s efficacy in determining disease aggressiveness.